An Open-Label, Single-Dose, Phase 1 Study of the Pharmacokinetics and Safety of JZP-110 in Subjects with Normal or Impaired Renal Function and with End-Stage Renal Disease Requiring Hemodialysis

Trial Profile

An Open-Label, Single-Dose, Phase 1 Study of the Pharmacokinetics and Safety of JZP-110 in Subjects with Normal or Impaired Renal Function and with End-Stage Renal Disease Requiring Hemodialysis

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs JZP 110 (Primary)
  • Indications Hypersomnia; Narcolepsy; Renal failure; Sleep apnoea syndrome
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Jazz Pharmaceuticals plc
  • Most Recent Events

    • 01 Sep 2017 Results published in the Clinical Pharmacology in Drug Development: 2017 Annual Meeting of the American College of Clinical Pharmacology
    • 09 Jun 2017 Results presented at the 31st Associated Professional Sleep Societies (APSS) Annual SLEEP Meeting.
    • 09 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top